

GILEAD SCIENCES INC
 Form 3
 July 29, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â YANG TAIYIN		(Month/Day/Year)	GILEAD SCIENCES INC [GILD]	
(Last)	(First)	(Middle)	07/27/2005	
GILEAD SCIENCES, INC., Â 333 LAKESIDE DRIVE			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
FOSTER CITY, Â CA Â 94404			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below)	(specify below)
			SVP, Pharm Dev & Mfg	6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	156,615	D	Â
Common Stock	3,992	I	by Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of	5. Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	------------------------------------	---------------------------------	---

Edgar Filing: GILEAD SCIENCES INC - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Incentive Stock Option (right to buy)	Â <u>(1)</u>	07/22/2008	Common Stock	12,000	\$ 2.8594	D	Â
Incentive Stock Option (right to buy)	Â <u>(2)</u>	01/25/2009	Common Stock	58,664	\$ 4.4688	D	Â
Incentive Stock Option (right to buy)	Â <u>(3)</u>	07/22/2009	Common Stock	11,624	\$ 7.2969	D	Â
Incentive Stock Option (right to buy)	Â <u>(4)</u>	01/18/2011	Common Stock	3,208	\$ 7.3985	D	Â
Incentive Stock Option (right to buy)	Â <u>(5)</u>	04/05/2010	Common Stock	4,800	\$ 7.4063	D	Â
Incentive Stock Option (right to buy)	Â <u>(6)</u>	07/20/2010	Common Stock	3,000	\$ 9.3438	D	Â
Incentive Stock Option (right to buy)	Â <u>(7)</u>	04/18/2011	Common Stock	2,000	\$ 9.81	D	Â
Incentive Stock Option (right to buy)	Â <u>(8)</u>	11/08/2010	Common Stock	1,888	\$ 11.7579	D	Â
Incentive Stock Option (right to buy)	Â <u>(9)</u>	01/30/2012	Common Stock	7,448	\$ 16.4375	D	Â
Incentive Stock Option (right to buy)	Â <u>(10)</u>	01/29/2013	Common Stock	4,414	\$ 17.885	D	Â
Incentive Stock Option (right to buy)	Â <u>(11)</u>	07/28/2014	Common Stock	290	\$ 29.115	D	Â
Incentive Stock Option (right to buy)	Â <u>(12)</u>	01/28/2014	Common Stock	3,000	\$ 30.53	D	Â
Incentive Stock Option (right to buy)	Â <u>(13)</u>	01/26/2015	Common Stock	2,000	\$ 32.02	D	Â
Incentive Stock Option (right to buy)	Â <u>(14)</u>	07/30/2013	Common Stock	1,578	\$ 34.995	D	Â
Incentive Stock Option	Â <u>(15)</u>	05/09/2015	Common Stock	928	\$ 38.72	D	Â
Non-Qualified Stock Option (right to buy)	Â <u>(4)</u>	01/18/2011	Common Stock	60,792	\$ 7.3985	D	Â
Non-Qualified Stock Option (right to buy)	Â <u>(5)</u>	04/05/2010	Common Stock	43,200	\$ 7.4063	D	Â
Non-Qualified Stock Option (right to buy)	Â <u>(6)</u>	07/20/2010	Common Stock	17,000	\$ 9.3438	D	Â
	Â <u>(8)</u>	11/08/2010		14,112	\$ 11.7579	D	Â

Edgar Filing: GILEAD SCIENCES INC - Form 3

Option Type	Grant Number	Grant Date	Common Stock	Exercise Price	Expiration	Other
Non-Qualified Stock Option (right to buy)	Â (9)	01/30/2012	Common Stock	72,552	\$ 16.4375	D Â
Non-Qualified Stock Option (right to buy)	Â (10)	01/29/2013	Common Stock	45,586	\$ 17.885	D Â
Non-Qualified Stock Option (right to buy)	Â (11)	07/28/2014	Common Stock	29,710	\$ 29.115	D Â
Non-Qualified Stock Option (right to buy)	Â (12)	01/28/2014	Common Stock	57,000	\$ 30.53	D Â
Non-Qualified Stock Option (right to buy)	Â (13)	01/26/2015	Common Stock	38,000	\$ 32.02	D Â
Non-Qualified Stock Option (right to buy)	Â (14)	07/30/2013	Common Stock	38,422	\$ 34.995	D Â
Non-Qualified Stock Option (right to buy)	Â (15)	05/09/2015	Common Stock	29,072	\$ 38.72	D Â
Incentive Stock Option (right to buy)	Â (16)	01/26/2010	Common Stock	2,000	\$ 7.0782	D Â
Non-Qualified Stock Option (right to buy)	Â (7)	04/18/2011	Common Stock	18,000	\$ 9.81	D Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
YANG TAIYIN GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404	Â	Â	Â SVP, Pharm Dev & Mfg	Â

Signatures

/s/ Taiyin Yang 07/29/2005

**Signature of
Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vest 20% on 7/22/99, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (2) Options vest 20% on 1/25/2000, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (3) Options vest 20% on 7/22/2000, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (4) Options vest 20% on 1/18/2002, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (5) Options vest 20% on 4/5/2001, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.

Edgar Filing: GILEAD SCIENCES INC - Form 3

- (6) Options vest 20% on 7/20/2001, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (7) Options vest 20% on 4/18/2002, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (8) Options vest 20% on 11/8/2001, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (9) Options vest 20% on 1/30/2003, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (10) Options vest 20% on 1/29/2004, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (11) Options vest 20% on 7/28/2005, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (12) Options vest 20% on 1/28/2005, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (13) Options vest 20% on 1/26/2006, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (14) Options vest 20% on 7/30/2004, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (15) Options vest 20% on 5/9/2006, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.
- (16) Options vest 20% on 1/26/2002, first anniversary date of the grant, and the remaining will vest quarterly over the next four years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.